• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)

Dictionary: Patient Representatives participate in advisory committee meetings to ensure patient input on important medical product review and policy questions.

The Patient Representative’s role is to provide the advisory committee and FDA insight on issues, problems, and/or questions pertinent to the unique viewpoint of patients living with a specific disease.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent
Oct 201080100
Nov 20108071
Dec 201080100
Jan 201180100
Feb 201180100
Mar 20118071
Apr 20118083
May 20118083
Jun 20118080
Jul 201180100
Aug 201180100
Sep 201180100

FY 2011 Overall: 88%

Footnotes

  • (1) This measure will no longer be tracked after April 2012.

Number of FDA advisory committee meetings during the month that had a Patient Representative (1)

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A3
Nov 2010N/A5
Dec 2010N/A9
Jan 2011N/A4
Feb 2011N/A1
Mar 2011N/A5
Apr 2011N/A5
May 2011N/A5
Jun 2011N/A4
Jul 2011N/A5
Aug 2011N/A1
Sep 2011N/A6

FY 2011 Total: 53

Number of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A3
Nov 2010N/A7
Dec 2010N/A9
Jan 2011N/A4
Feb 2011N/A1
Mar 2011N/A7
Apr 2011N/A6
May 2011N/A6
Jun 2011N/A5
Jul 2011N/A5
Aug 2011N/A1
Sep 2011N/A6

FY 2011 Total: 60

Total number of advisory committee meetings during the month (1)

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetNumber
Oct 2010N/A5
Nov 2010N/A10
Dec 2010N/A10
Jan 2011N/A5
Feb 2011N/A4
Mar 2011N/A8
Apr 2011N/A7
May 2011N/A9
Jun 2011N/A5
Jul 2011N/A5
Aug 2011N/A3
Sep 2011N/A7

FY 2011 Total: 78

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.